- Home
- GCEngine platform
- Solution
- Partners & Collaborations
- Company
Accurate translation begins with chemically and structurally pure modules. At the GCEngine platform, our tRNA purity evaluation service provides a rigorous multi-parameter analysis designed to help every tRNA batch meet analytical-grade standards for translational research and biomanufacturing. We assess tRNA purity at the chemical, structural, and functional levels, verifying that the molecule entering your ncAA or orthogonal translation system is homogeneous, intact, and free of unwanted variants.
tRNA purity goes beyond the absence of impurities—it encompasses sequence integrity, modification completeness, structural uniformity, and functional competence. Even trace contaminants—truncated RNAs, misprocessed species, or residual small RNAs—can skew quantification and interfere with aminoacylation or hybridization workflows.
On the GCEngine platform, tRNA purity evaluation quantifies composition and sequence homogeneity and flags process carry-over.
Scope note: Results are assay-agnostic and can be handed off to integrity or functional testing when needed. This page focuses on purity. Structural folding and activity belong to Integrity/Functional modules (see Related Services).
Fig.1 tRNA purification with step elution with CIM DEAE using HPLC or centrifuge. (Megušar, P., et al., 2024)
The GCEngine platform combines high-resolution analytical chemistry with functional biochemical testing to establish the purity profile of natural, synthetic, or modified tRNAs. Each assessment covers both quantitative purity (percent composition, contaminant level) and qualitative purity (functional and structural uniformity).
Our standardized yet customizable workflow can be applied to in-vitro-transcribed, enzymatically synthesized, or cell-derived tRNAs, as well as to modified and orthogonal species used for ncAA incorporation.
| Method Category | Technique | What It Measures | Purity Attribute | Description / Output |
| Composition & Homogeneity | HPLC / UPLC | Main peak, side peaks | Chemical purity / sample composition | Quantifies purity %, detects truncated RNAs, over-length products, and IVT/purification byproducts. |
| Chemical Identity Consistency | Nucleoside LC–MS/MS | Modification panel, nucleoside composition | Chemical identity purity | Confirms expected nucleosides; detects contamination nucleosides or batch inconsistency (not a structural readout). |
| DNA Contamination | Qubit dsDNA / qPCR | Genomic DNA or plasmid carryover | Process impurity | Sensitive detection of dsDNA contamination down to pg–ng levels. |
| Protein / Endotoxin Contamination | Bradford / BCA / LAL assays | Protein residuals / endotoxin units | Process impurity | Verifies that protein carryover from extraction is minimized and that endotoxin levels meet predefined thresholds (critical for mammalian applications). |
| Residual Solvents / Salt Impurities | Conductivity / specific ion/solvent assays | Buffers, salts, phenol, ethanol traces | Process impurity | Identifies chemical residues affecting downstream modification or enzymatic reactions. |
| RNase Contamination | RNase activity assay (fluorogenic substrate) | RNase presence | Stability-related impurity | Confirms no detectable RNase activity that could degrade tRNA during subsequent workflows. |
| Length / Species Heterogeneity | Denaturing PAGE / CE-SDS | Short fragments, double-length species, small-RNA impurities | Purity (heterogeneity only) | Quantifies off-size RNA species and low-level contaminants; no folding/structure interpretation. |
Purity defines performance—especially when decoding the expanded genetic alphabet. At the GCEngine platform, we combine analytical rigor with translational expertise to verify that every tRNA entering your system is molecularly pure, structurally uniform, and functionally active. Contact us today to schedule a customized tRNA purity evaluation and secure uncompromised quality for your next genetic code expansion project.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.